Pyrazolo[1,5-a]pyridine MIF Inhibitors for Broad Disease Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for deadly diseases such as malaria, cancer, inflammatory conditions, and neurodegenerative diseases, with no cure available and a need for new therapeutic approaches.
Innovation Solution
Development of pyrazolo[1,5-a]pyridine derivatives that act as inhibitors of macrophage migration inhibitory factor (MIF) to modulate parasite-induced pathologies and diseases, including parasitic infections, cancer, neurological disorders, inflammatory diseases, and cardiovascular conditions, through compounds of Formula (I) or their pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for deadly diseases such as malaria, cancer, and inflammatory conditions, then existing therapeutic protocols are maintained, but no cure is available and disease burden continues to increase
Solution Approach 1:
The patent describes pyrazolo[1,5-a]pyridine derivatives that function as inhibitors of macrophage migration inhibitory factor (MIF), a mechanism that applies across multiple disease types including parasitic infections, cancer, inflammatory conditions, and neurodegenerative diseases. This multi-functional approach allows a single compound class to address diverse pathological conditions through a common therapeutic mechanism, thereby improving both reliability of treatment and adaptability across disease types
2Reliability
If new therapeutic approaches are developed to combat deadly diseases, then potential cures and treatments become available, but the complexity of drug development and clinical validation increases
Solution Approach 1:
The patent employs systematic modification of chemical parameters in pyrazolo[1,5-a]pyridine derivatives, varying substituents at different positions (R1-R6, W, L, R8, R9) to optimize MIF inhibition activity. This parameter-based approach allows for structured drug development where chemical structure-activity relationships can be systematically explored, improving therapeutic efficacy while maintaining a manageable development framework through rational design rather than random screening
Data Source
AI summary
The present application provides a compound of Formula (I): [Formula I] or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, W, L, R8, and R9 are as described herein. Pharmaceutical compositions including these compounds and methods of using these compounds for treating parasitic infections (e.g., malaria), cancer, cardiovascular diseases, neurological diseases, inflammatory diseases, neuropathic pain, and other conditions are also disclosed herein.